ARFIP2 and diabetic kidney disease: In our study, we confirm ARFIP2 as a regulator of the cytoskeleton and co-factor of ATG9-mediated autophagosome formation in podocytes, showing for the first time that ARFIP2 acts as a novel regulator of mitophagic homeostasis in podocytes in diabetic nephropathy by adjusting the PINK1-Parkin pathway and participating in oxidative phosphorylation in vivo and in vitro.